Biologics Market Report 2026

The biologics market size has grown strongly in recent years. It will grow from $495.56 billion in 2025 to $540.46 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to limited biologics availability, reliance on traditional therapies, growing prevalence of immune-related disorders, increasing healthcare infrastructure, rising physician awareness and prescriptions.

The biologics market size is expected to see rapid growth in the next few years. It will grow to $827.24 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to development of novel monoclonal antibodies, expansion of mRNA and viral vector vaccines, increasing adoption of personalized biologic therapies, growing government support and funding for biologics, integration of digital health and patient monitoring platforms. Major trends in the forecast period include rising adoption of monoclonal antibodies and therapeutic proteins, growth in vaccine development including mrna and viral vector vaccines, expansion of prescription-based biologics and hospital pharmacy distribution, increasing focus on personalized medicine and targeted biologic therapies, integration of biologics with advanced healthcare solutions and patient monitoring.

The surging demand for personalized medicine is fueling robust expansion in the global biologics market. Personalized medicine, or precision medicine, customizes healthcare and therapies to match each patient's unique traits. It revolutionizes care by adapting biologic treatments to individual genetic and clinical makeup. For instance, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, noted the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the biologics market going forward.

Leading companies in the biologics market are advancing novel offerings like biosimilars to deliver affordable substitutes for pioneer biologic therapies. Biosimilars are biologic medicines closely matching approved reference versions, showing no notable variances in safety, effectiveness, or quality, thereby cutting costs and broadening access to sophisticated care. For instance, in July 2025, Biocon Biologics, a subsidiary of Biocon Limited, an India-based biopharmaceutical company, introduced Nepexto, a biosimilar to Enbrel (etanercept), in Australia. Nepexto is a fusion-protein biologic crafted to block tumor necrosis factor-alpha (TNF-α), a prime inflammatory driver in autoimmune disorders. It employs recombinant DNA-derived protein echoing the original etanercept's binding action, yielding equivalent efficacy and safety while enhancing reach. Its standout traits encompass strong biosimilarity proven by solid clinical evidence, regulatory nods, and reliable supply through partner Generic Health, positioning it well for ongoing management of rheumatoid arthritis, psoriasis, and ankylosing spondylitis.

In October 2025, Terumo Corporation, a Japan-based healthcare technology company, acquired the drug-product plant and quality-control laboratory operations of WuXi Biologics in Leverkusen, Germany for an undisclosed amount. Through this acquisition, Terumo Corporation seeks to widen its contract-development and manufacturing organization (CDMO) presence in Europe, refine integrated services for injectable therapeutics, and boost worldwide agility for biopharma customers. WuXi Biologics GmbH is a Germany-based life-sciences company that specializes in providing biopharmaceutical contract development and manufacturing services for biologics and advanced therapies.

Major companies operating in the biologics market are Merck & Co. Inc., AbbVie Inc., F. Hoffmann-La Roche AG, Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb Company, Sanofi S.A., GlaxoSmithKline Plc., Eli Lilly and Company, Amgen Inc., Shanghai Fosun Pharmaceuticals, Bayer AG, Novartis AG, BiosanaPharma, WuXi, Teva UK Limited, AstraZeneca, Abbott Laboratories, Vectura Group, Fujifilm, Lonza, Seqens, Piramal Pharma Solutions, Corden Pharma, Procos SpA and BSP Pharmaceuticals., Microgen, Geropharm, Valenta, NovaMedica, SynBi, Rani Therapeutics, Enteris BioPharma, Allena Pharmaceuticals, Biogen Inc., Emisphere Technologies Inc., Apotex, Gilead Sciences.

North America was the largest region in the biologics market in 2025. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biologics market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

Tariffs have influenced the biologics market by raising costs for imported raw materials, bioprocessing equipment, and specialized reagents, impacting production and supply chains. Segments such as monoclonal antibodies, therapeutic proteins, and vaccines are most affected, particularly in regions like North America and Europe that rely on imports. While tariffs have increased operational costs and slowed market expansion, they have also promoted local manufacturing, domestic innovation, and investment in cost-effective biologic production solutions.

The biologics market research report is one of a series of new reports that provides biologics market statistics, including biologics industry global market size, regional shares, competitors with a biologics market share, detailed biologics market segments, market trends and opportunities, and any further data you may need to thrive in the biologics industry. This biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biologics are medications derived from organic materials used to treat a variety of diseases, particularly immune-related conditions. They are obtained from diverse natural sources, including carbohydrates, proteins, nucleic acids, or complex combinations of these substances.

The main types of biologics are monoclonal antibodies (mAbs), therapeutic proteins, and vaccines. Monoclonal antibodies are laboratory-produced molecules designed to target specific infections or disease processes. These biologics can be administered through oral, parenteral, and other routes, and are distributed via hospital pharmacies, retail pharmacies, and other channels.

The biologics market consists of sales of tumor necrosis factor inhibitors, Interleukin inhibitors, B-cells inhibitors, and T-cells inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.